Sabby Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Sabby Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-28	Closed	-$32	–	307
2014 Q3	$32	Sell	28 -11	-28%	-$168	﹤0.01%	246
2014 Q2	$76K	Sell	39 -46	-54%	-$812	﹤0.01%	240
2014 Q1	$152K	Sell	85 -28	-25%	-$460	0.01%	213
2013 Q4	$120K	Sell	113 -73	-39%	-$816	0.01%	194
2013 Q3	$230K	Buy	+186	New	+$1.96K	0.01%	179

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Sabby Management's CASC Position: Q2 2017 in Review

Sabby Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 161,670 shares — an estimated $669K sold.

Sabby Management first reported a position in CASC in Q3 2013 and held it in 9 quarters. The position peaked at $1.36M in Q3 2013. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

Sabby Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 161,670 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $669K.
Sabby Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 9 quarters.
Sabby Management's Cascadian Therapeutics, Inc. position peaked at $1.36M in Q3 2013.
76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.